Xing Zeng

4.1k total citations
90 papers, 2.4k citations indexed

About

Xing Zeng is a scholar working on Molecular Biology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Xing Zeng has authored 90 papers receiving a total of 2.4k indexed citations (citations by other indexed papers that have themselves been cited), including 41 papers in Molecular Biology, 28 papers in Pulmonary and Respiratory Medicine and 11 papers in Surgery. Recurrent topics in Xing Zeng's work include Renal cell carcinoma treatment (9 papers), Natural product bioactivities and synthesis (9 papers) and Bladder and Urothelial Cancer Treatments (9 papers). Xing Zeng is often cited by papers focused on Renal cell carcinoma treatment (9 papers), Natural product bioactivities and synthesis (9 papers) and Bladder and Urothelial Cancer Treatments (9 papers). Xing Zeng collaborates with scholars based in China, United States and Canada. Xing Zeng's co-authors include Bruce M. Spiegelman, Mark P. Jedrychowski, Zhiquan Hu, Chunguang Yang, Bo Hu, Bradford B. Lowell, Jon M. Resch, Jonathan Z. Long, John J. Castellot and Rajesh R. Rao and has published in prestigious journals such as Nature, Cell and Proceedings of the National Academy of Sciences.

In The Last Decade

Xing Zeng

85 papers receiving 2.4k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Xing Zeng China 24 1.0k 858 555 240 232 90 2.4k
Juejin Wang China 28 1.2k 1.2× 724 0.8× 500 0.9× 287 1.2× 429 1.8× 64 2.5k
Liang Guo China 34 1.5k 1.4× 1.0k 1.2× 1.0k 1.8× 309 1.3× 282 1.2× 98 3.1k
Yuhong Liu China 25 1.0k 1.0× 598 0.7× 409 0.7× 100 0.4× 374 1.6× 106 2.2k
Hyeon Soo Kim South Korea 31 1.8k 1.8× 658 0.8× 364 0.7× 292 1.2× 94 0.4× 110 3.1k
Tae Woo Jung South Korea 32 1.1k 1.1× 812 0.9× 925 1.7× 148 0.6× 196 0.8× 111 2.7k
Somasundaram Arumugam Japan 32 1.0k 1.0× 294 0.3× 459 0.8× 133 0.6× 325 1.4× 86 2.8k
Hadi Al‐Hasani Germany 38 2.2k 2.2× 1.2k 1.4× 551 1.0× 323 1.3× 274 1.2× 138 4.2k
Xianglu Rong China 27 1.5k 1.4× 392 0.5× 518 0.9× 188 0.8× 336 1.4× 76 3.2k
Vicent Ribas Spain 27 1.1k 1.0× 521 0.6× 628 1.1× 324 1.4× 154 0.7× 51 2.7k

Countries citing papers authored by Xing Zeng

Since Specialization
Citations

This map shows the geographic impact of Xing Zeng's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xing Zeng with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xing Zeng more than expected).

Fields of papers citing papers by Xing Zeng

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Xing Zeng. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xing Zeng. The network helps show where Xing Zeng may publish in the future.

Co-authorship network of co-authors of Xing Zeng

This figure shows the co-authorship network connecting the top 25 collaborators of Xing Zeng. A scholar is included among the top collaborators of Xing Zeng based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Xing Zeng. Xing Zeng is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Tessier‐Cloutier, Basile, et al.. (2025). Use of doxorubicin and trabectedin in low-grade endometrial stromal sarcoma: A case report. Gynecologic Oncology Reports. 62. 101988–101988.
3.
Huang, Haijun, Sijuan Zou, Xing Zeng, et al.. (2024). 68Ga-PSMA PET/CT and 18F-FDG PET/CT in the diagnosis of prostatic ductal cancer. Urologic Oncology Seminars and Original Investigations. 42(12). 448.e9–448.e16. 1 indexed citations
4.
Li, Le, et al.. (2024). Tumor ABCC4-mediated release of PGE2 induces CD8+ T cell dysfunction and impairs PD-1 blockade in prostate cancer. International Journal of Biological Sciences. 20(11). 4424–4437. 6 indexed citations
5.
Tian, Jihua, Jing Luo, Xing Zeng, et al.. (2024). Targeting oxidative phosphorylation to increase the efficacy of immune-combination therapy in renal cell carcinoma. Journal for ImmunoTherapy of Cancer. 12(2). e008226–e008226. 12 indexed citations
6.
Levin, Gabriel, et al.. (2024). Doxorubicin and trabectedin for recurrent leiomyosarcoma – A case report. Gynecologic Oncology Reports. 55. 101497–101497. 1 indexed citations
7.
Tian, Jihua, et al.. (2023). Cytoreductive partial and radical nephrectomies provide equivalent oncologic outcomes in T1–2M1 renal cell carcinoma. Translational Cancer Research. 12(2). 301–309. 5 indexed citations
8.
Chen, Zhi, Ke Chen, Le Li, et al.. (2023). Non‐SMC condensin I complex subunit H participates in anti‐programmed cell death‐1 resistance of clear cell renal cell carcinomas. Cell Proliferation. 56(7). e13400–e13400. 16 indexed citations
9.
Huang, Hai, Yucong Zhang, Zhi Chen, et al.. (2023). Neoadjuvant therapy with Disitamab vedotin in treating muscle-invasive bladder cancer: A case report. Heliyon. 9(4). e15157–e15157. 1 indexed citations
10.
Tian, Jihua, Xing Zeng, Jie Wan, et al.. (2022). Partial and Radical Nephrectomy Provides Equivalent Oncologic Outcomes in pT3a Renal Cell Carcinoma: A Population-Based Study. Frontiers in Oncology. 11. 819098–819098. 4 indexed citations
11.
Zeng, Xing, Ke Chen, Le Li, et al.. (2022). Epigenetic activation of RBM15 promotes clear cell renal cell carcinoma growth, metastasis and macrophage infiltration by regulating the m6A modification of CXCL11. Free Radical Biology and Medicine. 184. 135–147. 46 indexed citations
12.
Hu, Zhiquan, et al.. (2022). Absence of PSA Flare With Apalutamide Administered 1 Hour in Advance With GnRH Agonists: Case Report. Frontiers in Oncology. 12. 878264–878264.
13.
Yu, Chong‐Jen, et al.. (2020). Clinical characteristics of confirmed and clinically diagnosed patients with 2019 novel coronavirus pneumonia: a single-center, retrospective, case-control study. Medicina Clínica (English Edition). 155(8). 327–334. 10 indexed citations
14.
Wang, Yufeng, et al.. (2020). 2019 Novel coronavirus disease (COVID-19) in hemodialysis patients: A report of two cases. Clinical Biochemistry. 81. 9–12. 17 indexed citations
15.
Wang, Jingrong, Weina Gao, Rudolf Grimm, et al.. (2017). A method to identify trace sulfated IgG N-glycans as biomarkers for rheumatoid arthritis. Nature Communications. 8(1). 631–631. 95 indexed citations
16.
Chen, Yi, et al.. (2017). Crosstalk between KCNK3-Mediated Ion Current and Adrenergic Signaling Regulates Adipose Thermogenesis and Obesity. Cell. 171(4). 836–848.e13. 68 indexed citations
17.
18.
Chen, Ruibao, Xing Zeng, Ruitao Zhang, et al.. (2013). Cav1.3 channel α1D protein is overexpressed and modulates androgen receptor transactivation in prostate cancers. Urologic Oncology Seminars and Original Investigations. 32(5). 524–536. 60 indexed citations
19.
He, Yi, Xian Zhang, Xing Zeng, et al.. (2012). HuR-mediated posttranscriptional regulation of p21 is involved in the effect of Glycyrrhiza uralensis licorice aqueous extract on polyamine-depleted intestinal crypt cells proliferation. The Journal of Nutritional Biochemistry. 23(10). 1285–1293. 8 indexed citations
20.
Ye, Qing, Zhihua Wang, Tong Lü, et al.. (2012). Generation and functional characterization of the anti-transferrin receptor single-chain antibody-GAL4 (TfRscFv-GAL4) fusion protein. BMC Biotechnology. 12(1). 91–91. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Juejin Wang Breakdown of academic impact, for papers by Liang Guo Breakdown of academic impact, for papers by Yuhong Liu Breakdown of academic impact, for papers by Hyeon Soo Kim Breakdown of academic impact, for papers by Tae Woo Jung Breakdown of academic impact, for papers by Somasundaram Arumugam Breakdown of academic impact, for papers by Hadi Al‐Hasani Breakdown of academic impact, for papers by Xianglu Rong Breakdown of academic impact, for papers by Vicent Ribas
Rankless by CCL
2026